

Health Care Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2018

| | Shares | Value |
|--|--------|-------------------|
| COMMON STOCKS[†] - 99.8% | | |
| Pharmaceuticals - 32.3% | | |
| Johnson & Johnson | 18,966 | \$ 2,301,334 |
| Pfizer, Inc. | 51,565 | 1,870,778 |
| Merck & Company, Inc. | 26,935 | 1,634,955 |
| AbbVie, Inc. | 16,176 | 1,498,706 |
| Bristol-Myers Squibb Co. | 22,335 | 1,236,019 |
| Eli Lilly & Co. | 14,334 | 1,223,120 |
| CVS Health Corp. | 15,408 | 991,505 |
| Allergan plc | 5,606 | 934,632 |
| Express Scripts Holding Co.* | 10,513 | 811,709 |
| Zoetis, Inc. | 9,454 | 805,386 |
| McKesson Corp. | 4,670 | 622,978 |
| Teva Pharmaceutical Industries Ltd. ADR | 25,263 | 614,396 |
| Mylan N.V.* | 15,187 | 548,858 |
| AmerisourceBergen Corp. — Class A | 6,118 | 521,682 |
| Cardinal Health, Inc. | 9,568 | 467,206 |
| GlaxoSmithKline plc ADR | 11,513 | 464,089 |
| Novartis AG ADR | 6,139 | 463,740 |
| Jazz Pharmaceuticals plc* | 2,685 | 462,626 |
| AstraZeneca plc ADR | 13,174 | 462,539 |
| Perrigo Company plc | 6,095 | 444,387 |
| Sarepta Therapeutics, Inc.* | 3,300 | 436,194 |
| Alkermes plc* | 9,550 | 393,078 |
| Neurocrine Biosciences, Inc.* | 3,830 | 376,259 |
| DexCom, Inc.* | 3,835 | 364,248 |
| Valeant Pharmaceuticals International, Inc.* | 14,604 | 339,397 |
| Nektar Therapeutics* | 6,898 | 336,829 |
| PRA Health Sciences, Inc.* | 3,310 | 309,022 |
| Agios Pharmaceuticals, Inc.* | 3,173 | 267,262 |
| Supernus Pharmaceuticals, Inc.* | 4,000 | 239,400 |
| Array BioPharma, Inc.* | 13,782 | 231,262 |
| Ironwood Pharmaceuticals, Inc. — Class A* | 11,520 | 220,262 |
| TESARO, Inc.* ¹ | 4,706 | 209,276 |
| Horizon Pharma plc* | 12,328 | 204,152 |
| Clovis Oncology, Inc.* | 4,380 | 199,159 |
| Global Blood Therapeutics, Inc.* | 4,300 | 194,360 |
| Portola Pharmaceuticals, Inc.* | 5,120 | 193,382 |
| Akom, Inc.* | 11,626 | 192,875 |
| Mallinckrodt plc* ¹ | 8,527 | 159,114 |
| Corcept Therapeutics, Inc.* | 9,900 | 155,628 |
| Pacira Pharmaceuticals, Inc.* | 4,142 | 132,751 |
| Total Pharmaceuticals | | 23,534,555 |
| Healthcare-Products - 23.2% | | |
| Abbott Laboratories | 21,318 | 1,300,185 |
| Thermo Fisher Scientific, Inc. | 5,524 | 1,144,241 |
| Danaher Corp. | 10,558 | 1,041,864 |
| Becton Dickinson and Co. | 4,336 | 1,038,732 |
| Stryker Corp. | 5,969 | 1,007,925 |
| Intuitive Surgical, Inc.* | 1,934 | 925,380 |
| Medtronic plc | 9,955 | 852,248 |
| Boston Scientific Corp.* | 25,942 | 848,303 |
| Baxter International, Inc. | 10,759 | 794,445 |
| Edwards Lifesciences Corp.* | 4,778 | 695,534 |
| Align Technology, Inc.* | 1,892 | 647,329 |
| Zimmer Biomet Holdings, Inc. | 5,376 | 599,101 |
| IDEXX Laboratories, Inc.* | 2,493 | 543,324 |
| ABIOMED, Inc.* | 1,280 | 523,584 |
| ResMed, Inc. | 4,672 | 483,926 |
| Teleflex, Inc. | 1,630 | 437,182 |
| Cooper Companies, Inc. | 1,816 | 427,577 |
| Henry Schein, Inc.* | 5,867 | 426,179 |
| Hologic, Inc.* | 10,263 | 407,954 |
| Dentsply Sirona, Inc. | 9,052 | 396,206 |
| Varian Medical Systems, Inc.* | 3,483 | 396,087 |
| ICU Medical, Inc.* | 1,040 | 305,396 |
| Integra LifeSciences Holdings Corp.* | 4,600 | 296,286 |
| Bio-Techne Corp. | 1,930 | 285,544 |
| Masimo Corp.* | 2,890 | 282,209 |
| Insulet Corp.* | 3,170 | 271,669 |
| NuVasive, Inc.* | 3,882 | 202,330 |
| Patterson Companies, Inc. ¹ | 8,314 | 188,478 |
| MiMedx Group, Inc.* ¹ | 18,326 | 117,103 |
| Total Healthcare-Products | | 16,886,321 |
| Biotechnology - 22.8% | | |
| Amgen, Inc. | 7,620 | 1,406,576 |
| Gilead Sciences, Inc. | 17,325 | 1,227,303 |
| Biogen, Inc.* | 3,369 | 977,818 |
| Celgene Corp.* | 12,230 | 971,307 |
| Shire plc ADR | 5,512 | 930,426 |
| Vertex Pharmaceuticals, Inc.* | 5,143 | 874,104 |
| Regeneron Pharmaceuticals, Inc.* | 2,337 | 806,242 |
| Illumina, Inc.* | 2,864 | 799,886 |
| Alexion Pharmaceuticals, Inc.* | 5,459 | 677,735 |
| BioMarin Pharmaceutical, Inc.* | 5,642 | 531,476 |
| Incyte Corp.* | 6,720 | 450,240 |
| Seattle Genetics, Inc.* | 6,397 | 424,697 |
| Alnylam Pharmaceuticals, Inc.* | 3,845 | 378,694 |
| Sage Therapeutics, Inc.* | 2,210 | 345,931 |
| Exelixis, Inc.* | 15,795 | 339,908 |
| Exact Sciences Corp.* | 5,454 | 326,095 |
| Bluebird Bio, Inc.* | 2,060 | 323,317 |
| FibroGen, Inc.* | 4,760 | 297,976 |
| Loxo Oncology, Inc.* | 1,670 | 289,712 |
| United Therapeutics Corp.* | 2,506 | 283,554 |
| Ligand Pharmaceuticals, Inc. — Class B* | 1,330 | 275,536 |
| Ionis Pharmaceuticals, Inc.* | 6,590 | 274,605 |
| Immunomedics, Inc.* ¹ | 11,100 | 262,737 |
| Ultragenyx Pharmaceutical, Inc.* | 3,160 | 242,909 |
| Spark Therapeutics, Inc.* | 2,841 | 235,121 |
| Amicus Therapeutics, Inc.* | 13,664 | 213,432 |
| Medicines Co.* | 5,705 | 209,373 |
| Intercept Pharmaceuticals, Inc.* | 2,470 | 207,258 |
| Myriad Genetics, Inc.* | 5,488 | 205,086 |
| Blueprint Medicines Corp.* | 3,090 | 196,153 |
| Puma Biotechnology, Inc.* | 3,300 | 195,195 |
| Spectrum Pharmaceuticals, Inc.* | 9,160 | 191,994 |
| ACADIA Pharmaceuticals, Inc.* | 11,791 | 180,049 |
| Editas Medicine, Inc.* | 4,549 | 162,991 |
| AnaptysBio, Inc.* | 2,180 | 154,867 |

| | | |
|-----------------------------------|--------|---------|
| ImmunoGen, Inc.* | 15,208 | 147,974 |
| Sangamo Therapeutics, Inc.* | 10,310 | 146,402 |
| Radius Health, Inc.* ¹ | 4,961 | 146,201 |

Health Care Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2018

| | Shares | Value |
|---|------------|----------------------|
| COMMON STOCKS[†] - 99.8% (continued) | | |
| Biotechnology - 22.8% (continued) | | |
| Esperion Therapeutics, Inc. ^{*,1} | 3,200 | \$ 125,408 |
| Dynavax Technologies Corp.* | 8,125 | 123,906 |
| Total Biotechnology | | 16,560,194 |
| Healthcare-Services - 16.1% | | |
| UnitedHealth Group, Inc. | 7,822 | 1,919,050 |
| Anthem, Inc. | 4,114 | 979,255 |
| Aetna, Inc. | 5,309 | 974,202 |
| Humana, Inc. | 2,738 | 814,911 |
| Cigna Corp. | 4,776 | 811,681 |
| HCA Healthcare, Inc. | 7,332 | 752,263 |
| Centene Corp.* | 5,253 | 647,222 |
| IQVIA Holdings, Inc.* | 5,742 | 573,166 |
| Laboratory Corporation of America Holdings* | 2,989 | 536,615 |
| Quest Diagnostics, Inc. | 4,471 | 491,542 |
| DaVita, Inc.* | 6,334 | 439,833 |
| WellCare Health Plans, Inc.* | 1,758 | 432,890 |
| Universal Health Services, Inc. — Class B | 3,682 | 410,322 |
| Molina Healthcare, Inc.* | 3,236 | 316,934 |
| Envision Healthcare Corp.* | 6,646 | 292,490 |
| Syneos Health, Inc.* | 5,919 | 277,601 |
| MEDNAX, Inc.* | 5,996 | 259,507 |
| Acadia Healthcare Company, Inc.* | 5,970 | 244,233 |
| Tenet Healthcare Corp.* | 6,820 | 228,947 |
| LifePoint Health, Inc.* | 3,406 | 166,213 |
| Tivity Health, Inc.* | 4,360 | 153,472 |
| Total Healthcare-Services | | 11,722,349 |
| Electronics - 2.6% | | |
| Agilent Technologies, Inc. | 8,889 | 549,696 |
| Waters Corp.* | 2,599 | 503,140 |
| Mettler-Toledo International, Inc.* | 842 | 487,207 |
| PerkinElmer, Inc. | 4,827 | 353,481 |
| Total Electronics | | 1,893,524 |
| Software - 2.4% | | |
| Corner Corp.* | 9,391 | 561,488 |
| Veeva Systems, Inc. — Class A* | 5,282 | 405,974 |
| athenahealth, Inc.* | 2,050 | 326,237 |
| Medidata Solutions, Inc.* | 3,445 | 277,529 |
| Allscripts Healthcare Solutions, Inc.* | 15,196 | 182,352 |
| Total Software | | 1,753,580 |
| Commercial Services - 0.4% | | |
| HealthEquity, Inc.* | 3,530 | 265,103 |
| Total Common Stocks (Cost \$64,508,328) | | 72,615,626 |
| RIGHTS^{†††} - 0.0% | | |
| Dyax Corp. ^{*,2} | 5,700 | — |
| Total Rights (Cost \$—) | | — |
| Face Amount | | |
| REPURCHASE AGREEMENTS^{††,3} - 0.4% | | |
| JPMorgan Chase & Co. issued 06/29/18 at 2.10% due 07/02/18 | \$ 166,883 | 166,883 |
| Barclays Capital issued 06/29/18 at 2.07% due 07/02/18 | 81,948 | 81,948 |
| Bank of America Merrill Lynch issued 06/29/18 at 2.08% due 07/02/18 | 54,632 | 54,632 |
| Total Repurchase Agreements (Cost \$303,463) | | 303,463 |
| Shares | | |
| SECURITIES LENDING COLLATERAL^{†,4} - 1.1% | | |
| Money Market Fund | | |
| First American Government Obligations Fund — Class Z, 1.77% ⁵ | 799,949 | 799,949 |
| Total Securities Lending Collateral (Cost \$799,949) | | 799,949 |
| Total Investments - 101.3% (Cost \$65,611,740) | | \$ 73,719,038 |
| Other Assets & Liabilities, net - (1.3)% | | (978,997) |
| Total Net Assets - 100.0% | | \$ 72,740,041 |

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

¹ All or a portion of this security is on loan at June 30, 2018.

² Security was fair valued by the Valuation Committee at June 30, 2018. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

³ Repurchase Agreements.

⁴ Securities lending collateral.

⁵ Rate indicated is the 7 day yield as of June 30, 2018.

ADR — American Depositary Receipt

plc — Public Limited Company